Boryung finalizes Taxotere global acquisition at KRW 279.6B (down KRW 8.2B from initial), bolstering long-term growth
Final price confirmed upon closing: Boryung's acquisition of Sanofi's global business rights for Taxotere (docetaxel) in 19 countries closed on May 29, 2026, with a final consideration of approximately KRW 279.6B (EUR 170M).
Reduction of KRW 8.17B from initial agreement: The final amount decreased due to agreed adjustments, lowering the acquisition burden.
Payment structure: KRW 256.6B (EUR 156M) paid at closing; an additional KRW 23B (EUR 14M) contingent on future conditions.
Deal size at 35.64% of equity: The price represents 35.64% of 2024 year-end equity (KRW 784.5B), a significant but manageable outlay.
Strategic importance: Boryung's third anti-cancer brand acquisition (after Gemzar in 2020 and Alimta in 2022) and first to secure global rights for an original drug, expected to drive overseas expansion.
Impact on shareholders: No share issuance or dilution. While short-term cash outflow is substantial, the strong brand recognition and steady revenue stream of Taxotere should enhance long-term profitability.
[AI Summary]Boryung finalized the acquisition of Sanofi's Taxotere global rights at a reduced price, easing financial strain and laying groundwork for long-term overseas revenue growth. Without dilution, securing global rights to an original brand is positive for shareholder value, but the large deal size (35.6% of equity) warrants monitoring of cash flows.
KOSPI Filing Information
Filing: [Correction of Description] Important Management Matters Related to Investment Decision (Regarding the Global Business Acquisition Contract of Breast Cancer Treatment Taxotere)